Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : Health Systems Can Lower Operational Costs and Reduce Environmental Impact with CareAdvantage from the Johnson & Johnson Medical Devices Companies

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 05:32pm CET

By a News Reporter-Staff News Editor at Ecology, Environment & Conservation -- With health systems focused on finding new ways to address their impact on the environment and reduce costs, CareAdvantage from the Johnson & Johnson Medical Devices Companies* now has a new Sustainability capability. Designed to help health systems achieve specific environmental, waste management, cost savings, and sustainable purchasing goals, this offering from the Johnson & Johnson Medical Devices Companies (JJMDC)* * draws on more than 25 years of sustainability commitments by the Johnson & Johnson Family of Companies, including its leadership in medical device reprocessing and its deep commitment to its Health for Humanity 2020 Goals.

There is a growing demand for sustainability strategies in the healthcare ecosystem among U.S. health system executives and operating room clinicians, according to insights from a new JJMDC survey, called the Voices for Value Insights Seriesii. The survey found that nine out of 10 clinicians (92%) and health system executives (88%) agree that sustainability provides long-term cost savings. The majority also agree that sustainability provides additional benefits, such as protecting the environment (76%), improving patient care (73%), and increasing the ability to manage risk and regulatory performance (68%). Nearly all (95%) believe that environmental sustainability contributes to the value of care delivered in their health system. The survey was conducted online between September 7 and 13, 2017 among 92 executives and clinicians at large U.S. health systems.

"Sustainability is critically important to Intermountain Healthcare, but recycling alone is not going to help us reach our goals," said Steve Bergstrom, Director of Sustainability at Intermountain Healthcare. "Our collaboration helps us reduce waste and operating room expenses through a more circular systems approach that is saving hundreds of thousands of dollars on medical device costs and diverting tens of thousands of pounds of Intermountain waste from landfills each year."

The CareAdvantage Sustainability capability enables best-in-class reprocessing across a broad spectrum of product categories, to include both JJMDC as well as non-JJMDC reprocessed single-use devices. It also includes practical tools and educational resources to help health systems create sustainability programs with financial and environmental benefits while implementing best practices for measuring and communicating the value of sustainability in healthcare.

The CareAdvantage Sustainability capability can also help purchasing and sustainability teams in healthcare delivery systems meet their Environmental Preferable Purchasing (EPP) goals. Specific expertise is designed to help healthcare delivery systems build a consistent approach to EPP assessments. In addition, through EARTHWARDS®, the Johnson & Johnson approach for encouraging the development of more sustainable products, health systems can access devices which have been designed with factors such as reducing materials, minimizing packaging, and reducing energy usage in mind.

"Drawing on our extensive experience in sustainability, we can provide health systems with a broad portfolio of sustainably sourced medical devices to help them meet their commitment to environmental stewardship efficiently and cost effectively," said Melinda Thiel, Vice President, Customer Marketing & Solutions at JJMDC. "This is just one element of how we approach customer needs, which starts with listening and leads to a holistic, tailored approach to help them reach their goals and deliver measurable results."

For more information about CareAdvantage and its capabilities, including Sustainability, visit www.careadvantagejjmdc.com. Join the discussion about value-based care on Voices for Value on LinkedIn.

Keywords for this news article include: Environment, Johnson & Johnson Medical Devices Companies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Science Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
09:49aJOHNSON & JOHNSON : FDA Breakthrough Therapy Designation for Erdafitinib in the ..
09:49aJOHNSON & JOHNSON : Platinum Equity Submits Binding Offer to Acquire LifeScan Fr..
03/16JOHNSON & JOHNSON : J&J nears diabetes device exit with $2.1 bln LifeScan sale
03/16JOHNSON & JOHNSON : nears diabetes device exit with $2.1 billion LifeScan sale
03/16JOHNSON & JOHNSON : Janssen Announces U.S. FDA Breakthrough Therapy Designation ..
03/16JOHNSON & JOHNSON : Platinum Equity Submits Binding Offer to Acquire LifeScan Fr..
03/16JOHNSON & JOHNSON : Announces Binding Offer from Platinum Equity to Acquire Life..
03/16JOHNSON & JOHNSON : Mylan propose ways to cut TB drugs prices in India
03/15JOHNSON & JOHNSON : - New Late-Breaking Study Finds Wearable Electrocardiogram M..
03/15JOHNSON & JOHNSON : - INVOKANA Significantly Reduces the Risk of Heart Failure-R..
More news
News from SeekingAlpha
03:02pJOHNSON & JOHNSON : A Dividend King For Strong Returns 
08:00aRETIRE RICH : How To Buy Low And Sell High 
03/16COCA-COLA : Dividend King But With Poor Total Return 
03/16RETIREMENT STRATEGY : Cash Could Set You Free And Make You Money 
03/16YOUR DAILY PHARMA SCOOP : Abeona Update, Alexion Data, Solid Biosciences Setback 
Financials ($)
Sales 2018 81 115 M
EBIT 2018 24 940 M
Net income 2018 19 683 M
Debt 2018 12 439 M
Yield 2018 2,70%
P/E ratio 2018 18,56
P/E ratio 2019 17,42
EV / Sales 2018 4,57x
EV / Sales 2019 4,23x
Capitalization 359 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 150 $
Spread / Average Target 12%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-4.77%358 615
PFIZER0.99%218 946
NOVARTIS-5.34%216 150
ROCHE HOLDING LTD.-10.73%201 801
MERCK AND COMPANY-1.07%148 965
AMGEN8.25%136 727